Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 14  |  Issue : 7  |  Page : 1600--1605

Comparison of treatment efficacy between adjuvant intravenous chemotherapy and intravenous chemotherapy combined with intraperitoneal perfusion chemotherapy to treat postresection colon cancer


Tao Jiang1, Rui Feng2, Zhangchi Pan2, Qian Xu1, Wenyu Gao3, Sheng Yang1, Qiang Chen4 
1 Department of Medical Oncology, Fujian Medical University Union Hospital; Teaching and Researching Department of Oncology, Union Clinical Medical College of Fujian Medical University, Fujian, China
2 Department of Medical Oncology, Fujian Medical University Union Hospital, Fujian, China
3 Department of Digestive, Fujian Medical University Union Hospital, Fujian, China
4 Department of Medical Oncology, Fujian Medical University Union Hospital; Teaching and Researching Department of Oncology, Union Clinical Medical College of Fujian Medical University; Department of Digestive, Fujian Key Laboratory of Translational Cancer Medicine; Department of Digestive, Fujian Medical University Stem Cell Research Institute, Fujian, China

Correspondence Address:
Qiang Chen
Department of Medical Oncology, Fujian Medical University Union Hospital, Fujian; Teaching and Researching Department of Oncology, Union Clinical Medical College of Fujian Medical University, Fujian; Fujian Key Laboratory of Translational Cancer Medicine, Fujian; Fujian Medical University Stem Cell Research Institute, Fujian
China
Sheng Yang
Department of Medical Oncology, Fujian Medical University Union Hospital, Fujian; Teaching and Researching Department of Oncology, Union Clinical Medical College of Fujian Medical University, Fujian
China

Background: Surgery has been the definitive treatment for locoregional colon cancer. But approximately 40% of patients died from peritoneal seeding and tumor recurrence. To prevent peritoneal recurrence, the eradication of intraperitoneal cancer cells has been critical for improving postoperative survival. This study focused on the role of IPC in postoperative treatment of colon cancer. Patients and Methods: Seventy colon cancer patients who underwent radical resection from September 2009 to September 2012 received adjuvant therapy. Specifically, 39 individuals received intravenous chemotherapy (IVC), and 31 received combined IVC and intraperitoneal perfusion chemotherapy (IVC + IPC). Disease-free survival (DFS) for those received IVC (20.71 months) was shorter than those received IVC + IPC (25.71 months). DFS in IVC group was also shorter than that in the IVC + IPC group, for patients with Stage III pathological tumor staging, T4 invasion depth, N2 lymph node metastasis, and low to undifferentiated tumor tissue. Peritoneal metastasis in the IVC + IPC group was less, but the toxicity was similar. No significant difference was observed among IPC treatment groups using three drugs. In the IVC + IPC group, DFS of patients received >5 or 3–5 times of IPC was longer than those received <3 times of treatment. No significant difference was observed in DFS between patients who received >5 times or 3–5 times of IPC. Conclusion: After radical resection, patients who received IVC + IPC showed prolonged DFS than those received IVC, as well as fewer peritoneal metastasis. Compared to IPC, no significantly increased side effects or complications were occurred after IVC + IPC. More work should be performed to confirm that IVC + IPC was superior to IVC for treating postresection colon cancer.


How to cite this article:
Jiang T, Feng R, Pan Z, Xu Q, Gao W, Yang S, Chen Q. Comparison of treatment efficacy between adjuvant intravenous chemotherapy and intravenous chemotherapy combined with intraperitoneal perfusion chemotherapy to treat postresection colon cancer.J Can Res Ther 2018;14:1600-1605


How to cite this URL:
Jiang T, Feng R, Pan Z, Xu Q, Gao W, Yang S, Chen Q. Comparison of treatment efficacy between adjuvant intravenous chemotherapy and intravenous chemotherapy combined with intraperitoneal perfusion chemotherapy to treat postresection colon cancer. J Can Res Ther [serial online] 2018 [cited 2022 Nov 27 ];14:1600-1605
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2018;volume=14;issue=7;spage=1600;epage=1605;aulast=Jiang;type=0